Año 2019 / Volumen 111 / Número 8
Original
Treat to target in inflammatory bowel disease: a survey of treatment strategies amongst Portuguese doctors

593-597

DOI: 10.17235/reed.2019.6029/2018

Sónia Bernardo, Samuel R. Fernandes, Luís Araújo-Correia,

Resumen
Background: treatment goals in inflammatory bowel disease have changed over the last few years and have shifted from a mainly symptom-based management to objective endpoints, such as mucosal healing and deep remission. A treat-to-target strategy to achieve these goals has been proposed by several experts, although the real-life clinical data is still lacking. This study aimed to investigate the current practices among Portuguese gastroenterologists who treat inflammatory bowel disease patients. Methods: Portuguese gastroenterologists were asked to participate in an anonymous online survey. The questions focused on opinions and current practice with regard to treatment targets in inflammatory bowel disease. Results: sixty-two physicians agreed to participate in the survey, 40 were gastroenterology specialists and 22 (35.5%) were fellows. Deep remission was considered as the main treatment goal for Crohn’s disease and ulcerative colitis by 82% and 83.9% of the participants, respectively. Mucosal healing as a treatment target was used by 95% and 80% of participants in ulcerative colitis and Crohn’s disease, respectively; 71% intensified the treatment to achieve mucosal healing after clinical remission. The most common definition of mucosal healing in Crohn’s disease and ulcerative colitis was the absence of mucosal ulceration (32.3%) and a Mayo endoscopic sub-score of 0 (41.9%). Only 3.2% escalated treatment with the aim to achieve histologic remission in ulcerative colitis. Conclusion: a treat-to-target strategy to achieve mucosal healing and deep remission is currently accepted by a substantial number of Portuguese gastroenterologists.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. S. Vermeire, G. Van Assche, P. Rutgeerts. Review article: altering the natural history of Crohn´s disease- evidence for and agains current therapies. Aliment Pharmacol Ther. 2006;25:3-12.
2. Tessa E.H, et al. Treatment targets in inflammatory Bowel Disease: Current Status in Daily practice. J Gastrointestin Liver Dis. 2016;25:465-471.
3. Froslie KF, Jahnsen J, Moum BA, et al and the IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–422.
4. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut.2007;56:453–455.
5. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006;63:433–42.
6. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterol. 2011;141:1194-1201.
7. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5:477-483.
8. Van Assche G, Dignass A, Panés J, et al. The Second European Evidence Based Consensus on the Diagnosis and Management of Crohn’s Disease: Definitions and diagnosis. J Crohns Colitis.2010;4:7-27.
9. Dignass A, Eliakim R, Magro F, et al. Second European Evidence-based Consensus on the Diagnosis and Management of Ulcerative Colitis part 1: definitions and diagnosis. J Crohns Colitis.2012;6:965-990.
10. Peyrin-Biroulet L, et al. The Natural History of Adult Crohn´s Disease in Population-Based Cohorts. Am J Gastroenterol.2010;105:289-297.
11. Peyrin-Biroulet L, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;1-15.
12. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the
endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535-542.
13. Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterol. 2013;145:987-995.
14. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983-989.
15. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc.2004;60:505-512.
16. Fernandes SR, et al. Disagreement Among Gastroenterologists Using the Mayo and Rutgeerts Endoscopic Scores. Inflamm Bowel Dis. 2018;24(2):254-260.
17. William J. Sandborn, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel disease. J Crohns Colitis 2014;8:927-935.
18. D. Laharie, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther. 2013;37:998-1004.
19. Schoepfer AM, et al. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis.2012;6:412-418.
20. Inoue N, et al. Endoscopic remission (Mayo score 0 rather than score 1) predicts long-term clinical remission in ulcerative colitis. J Crohns Colitis.2013;7:S95.
21. Fernandes SR, et al. Transmural healing is associated with improved long-term outcomes of patients with Crohn´s disease. Inflamm Bowel Dis. 2017;23(8):1403-1409.
Artículos relacionados

Carta

Linfoma T hepatoesplénico y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2023.9472/2023

Carta

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Revisión

Enfermedad inflamatoria intestinal y trasplante de órganos sólido

DOI: 10.17235/reed.2020.7361/2020

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Caso Clínico

Lesiones serradas en pacientes con enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2019.5910/2018

Editorial

Redes sociales online y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2018.5496/2018

Carta al Editor

Hipertensión portal idiopática por tiopurinas

DOI: 10.17235/reed.2018.5256/2017

Instrucciones para citar
Bernardo S, Fernandes S, Araújo-Correia L. Treat to target in inflammatory bowel disease: a survey of treatment strategies amongst Portuguese doctors. 6029/2018


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 686 veces.
Este artículo ha sido descargado 159 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 06/11/2018

Aceptado: 01/02/2019

Prepublicado: 13/06/2019

Publicado: 31/07/2019

Tiempo de revisión del artículo: 85 días

Tiempo de prepublicación: 219 días

Tiempo de edición del artículo: 267 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas